外科常见腹腔感染多学科诊治专家共识

2021-03-18 中华医学会外科学分会 中华外科杂志.2021.59(3):161-178.

腹腔感染是临床常见的急危重症之一,其诊治涉及外科、重症医学、感染、检验、临床药学等多个学科,包括局部病灶处置、病原学检测、抗菌药物合理应用及因感染导致的全身各系统异常状况纠正等过程,具有特殊性及复杂性

中文标题:

外科常见腹腔感染多学科诊治专家共识

发布日期:

2021-03-18

简要介绍:

腹腔感染是临床常见的急危重症之一,其诊治涉及外科、重症医学、感染、检验、临床药学等多个学科,包括局部病灶处置、病原学检测、抗菌药物合理应用及因感染导致的全身各系统异常状况纠正等过程,具有特殊性及复杂性。本共识参考国内外最新进展并结合临床经验,以问题为导向,以循证为基础,对急性阑尾炎、上消化道穿孔、下消化道穿孔、急性胆道感染、肝脓肿、重症急性胰腺炎、胰瘘、胆瘘、吻合口瘘、内镜诊治后消化道穿孔等外科常见腹腔感染的诊断、病原学检测、外科及抗菌药物治疗等临床热点问题进行评述,并根据证据等级提出诊治相关的推荐意见,旨在规范外科常见腹腔感染的诊疗行为,在临床决策、抗菌药物应用等方面为临床医师提供参考及指导,以提高诊治水平并改善患者预后。

下载附件:

(因为版权问题,不支持下载)

评论区 (19)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1203669, encodeId=7c82120366935, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce496545404, createdName=ms7000001031705413, createdTime=Fri Mar 18 07:15:45 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182953, encodeId=12721182953c0, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82996400906, createdName=ms2000001826525154, createdTime=Mon Jan 10 21:11:47 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080895, encodeId=295e10808950a, content=支持, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d852717242, createdName=gghhzb, createdTime=Thu Dec 16 22:16:07 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051369, encodeId=6eed10513691e, content=支持, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7265200961, createdName=牛医生, createdTime=Wed Sep 15 07:42:24 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051368, encodeId=a99310513683d, content=支持, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7265200961, createdName=牛医生, createdTime=Wed Sep 15 07:42:20 CST 2021, time=2021-09-15, status=1, ipAttribution=)]
    2022-03-18 ms7000001031705413

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1203669, encodeId=7c82120366935, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce496545404, createdName=ms7000001031705413, createdTime=Fri Mar 18 07:15:45 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182953, encodeId=12721182953c0, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82996400906, createdName=ms2000001826525154, createdTime=Mon Jan 10 21:11:47 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080895, encodeId=295e10808950a, content=支持, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d852717242, createdName=gghhzb, createdTime=Thu Dec 16 22:16:07 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051369, encodeId=6eed10513691e, content=支持, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7265200961, createdName=牛医生, createdTime=Wed Sep 15 07:42:24 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051368, encodeId=a99310513683d, content=支持, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7265200961, createdName=牛医生, createdTime=Wed Sep 15 07:42:20 CST 2021, time=2021-09-15, status=1, ipAttribution=)]
    2022-01-10 ms2000001826525154

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1203669, encodeId=7c82120366935, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce496545404, createdName=ms7000001031705413, createdTime=Fri Mar 18 07:15:45 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182953, encodeId=12721182953c0, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82996400906, createdName=ms2000001826525154, createdTime=Mon Jan 10 21:11:47 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080895, encodeId=295e10808950a, content=支持, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d852717242, createdName=gghhzb, createdTime=Thu Dec 16 22:16:07 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051369, encodeId=6eed10513691e, content=支持, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7265200961, createdName=牛医生, createdTime=Wed Sep 15 07:42:24 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051368, encodeId=a99310513683d, content=支持, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7265200961, createdName=牛医生, createdTime=Wed Sep 15 07:42:20 CST 2021, time=2021-09-15, status=1, ipAttribution=)]
    2021-12-16 gghhzb

    支持

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1203669, encodeId=7c82120366935, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce496545404, createdName=ms7000001031705413, createdTime=Fri Mar 18 07:15:45 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182953, encodeId=12721182953c0, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82996400906, createdName=ms2000001826525154, createdTime=Mon Jan 10 21:11:47 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080895, encodeId=295e10808950a, content=支持, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d852717242, createdName=gghhzb, createdTime=Thu Dec 16 22:16:07 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051369, encodeId=6eed10513691e, content=支持, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7265200961, createdName=牛医生, createdTime=Wed Sep 15 07:42:24 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051368, encodeId=a99310513683d, content=支持, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7265200961, createdName=牛医生, createdTime=Wed Sep 15 07:42:20 CST 2021, time=2021-09-15, status=1, ipAttribution=)]
    2021-09-15 牛医生

    支持

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1203669, encodeId=7c82120366935, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce496545404, createdName=ms7000001031705413, createdTime=Fri Mar 18 07:15:45 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182953, encodeId=12721182953c0, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82996400906, createdName=ms2000001826525154, createdTime=Mon Jan 10 21:11:47 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080895, encodeId=295e10808950a, content=支持, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d852717242, createdName=gghhzb, createdTime=Thu Dec 16 22:16:07 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051369, encodeId=6eed10513691e, content=支持, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7265200961, createdName=牛医生, createdTime=Wed Sep 15 07:42:24 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051368, encodeId=a99310513683d, content=支持, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7265200961, createdName=牛医生, createdTime=Wed Sep 15 07:42:20 CST 2021, time=2021-09-15, status=1, ipAttribution=)]
    2021-09-15 牛医生

    支持

    0

拓展阅读

中国腹腔感染诊治指南(2019版)

中华医学会外科学分会外科感染与重症医学学组 · 2020-01-03

2022 韩国指南:抗生素在成人腹腔感染治疗中的应用

韩国感染病学会(KSID,Korean Society of Infectious Diseases) · 2022-12-21